Company: Gilead Sciences
Starting stock price: $32.16
Ending stock price: $46.01
Percent Change: 43.06%
Scoop: Gilead's big achievement of '07 was the FDA approval of Letairis [1], a hypertension drug that marked the company's entry into the lucrative cardiovascular space. The company reported strong Phase III results for aztreonam lysine for cystic fibrosis, and Gilead's late-stage hepatitis B treatment Viread is closing in on FDA approval [2]. Booming sales and an EU approval [3] of HIV treatment Atripla rounded out a great year for Gilead.
Current stock price (3/25): $51.01
Links:
[1] http://www.fiercebiotech.com/story/gilead-shares-surge-on-letairis-approval/2007-06-18
[2] http://www.fiercebiotech.com/story/gilead-touts-phase-iii-hep-b-results/2007-06-25
[3] http://www.fiercepharma.com/story/three-way-hiv-combo-approved-eu/2007-12-18
[4] http://www.fiercebiotech.com/special-reports/big-biotechs-stock-report
[5] http://www.fiercebiotech.com/special-reports/biogen-idec-big-biotechs-stock-report